Domainex and Pharmidex form drug discovery services alliance
Contract research company Domainex, based in Cambridge, UK and Pharmidex have agreed to combine their expertise and innovative technologies to provide the market with an integrated, high-quality drug discovery services platform.
Contract research company Domainex, based in Cambridge, UK and Pharmidex have agreed to combine their expertise and innovative technologies to provide the market with an integrated, high-quality drug discovery services platform.
They will amalgamate Domainex's LeadBuilder technology for cost-effective hit-finding, as well as its medicinal chemistry team, with London-based Pharmidex's in vitro and in vivo capabilities in drug metabolism and pharmacokinetics (DMPK).
The companies say the alliance will place particular emphasis on tackling the most challenging of scientific problems, including novel or "difficult" drug targets.
"Pharmidex and Domainex have both identified clients who wish to be supported with an integrated discovery and lead characterisation platform. By forming this alliance we can offer this option," said Eddy Littler, ceo of Domainex.
Mohammad Alavijeh, ceo of Pharmidex added: "We believe that this alliance of skills and expertise will enable us to extend our client-base in multiple drug discovery sectors."
